Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia (CLL).

PURPOSE: CD38 has emerged as a high-impact therapeutic target in multiple myeloma, with the approval of daratumumab (anti-CD38 monoclonal antibody). The clinical importance of CD38 in chronic lymphocytic leukemia (CLL) patients has been known for over two decades, though it’s relevance as a therapeu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Manna, Alak, Aulakh, Sonikpreet, Jani, Prachi, Ahmed, Salman, Akhtar, Sharoon, Coignet, Marie, Heckman, Michael G., Meghji, Zahara, Bhatia, Kirtipal, Sharma, Aarushi, Sher, Taimur, Alegria, Victoria, Malavasi, Fabio, Chini, Eduardo N., Chanan-Khan, Asher, Ailawadhi, Sikander, Paulus, Aneel
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6744942/
https://ncbi.nlm.nih.gov/pubmed/30940652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3412
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak